Restricted accessResearch articleFirst published online 2011-3
Myocardial perfusion imaging using a technetium-99m Sestamibi in asymptomatic and low risk for coronary artery disease patients with diagnosed systemic lupus erythematosus
Introduction: The aim of the present study was to evaluate technetium-99m sestamibi single photon emission tomography (SPECT) myocardial perfusion imaging (MPI) and its association with some clinical and laboratory parameters in an asymptomatic systemic lupus erythematosus (SLE) population.
Materials and Methods : Twenty-one subjects with SLE and no suspected or documented coronary artery disease (CAD) accomplished myocardial perfusion imaging. Some SLE and CAD parameters were also evaluated in association with myocardial SPECT.
Results: Twenty-one women with a diagnosis of SLE (mean age 36.9 ± 12.8) entered the study. All patients were in the low-risk category for CAD pretest; however, abnormal myocardial perfusion results were found in eight (38%) patients. Amongst the traditional CAD risk factors, there was a significant association between the presence of dyslipidemia and myocardial perfusion abnormalities (P= 0.047). However, we found no significant association between other traditional and SLE-specific risk factors.
Conclusion: This study’s significant finding was that asymptomatic CAD is common in SLE patients, even in those thought to be low risk for CAD and in the absence of cardiac symptoms.
Asanuma Y., Oeser A., Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med2003 Dec 18; 349(25): 2407-2415.
2.
Roman MJ, Shanker BA, Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med2003 Dec 18; 349(25): 2399-2406.
3.
Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A.Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis2003 Nov; 62(11): 1066-1070.
4.
Sella EM, Sato EI, Barbieri A.Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum2003 Nov; 48(11): 3168-3175.
5.
Bessant R., Duncan R., Ambler G., et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum2006 Dec 15; 55(6): 892-899.
6.
Sun SS, Shiau YC, Tsai SC, Lin CC, Kao A., Lee CCThe role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints . Rheumatology (Oxford) 2001 Oct; 40(10): 1106-1111.
7.
Goldberg RJ, Urowitz MB, Ibanez D., Nikpour M., Gladman DDRisk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol2009 Nov; 36(11): 2454-2461.
8.
Schillaci O. , Lagana B., Danieli R., et al. Technetium-99m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med1999 Jul; 26(7): 713-717.
9.
Bruce IN, Burns RJ, Gladman DD, Urowitz MBSingle photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol2000 Oct; 27(10): 2372-2377.
10.
Lin CC, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A.Usefulness of technetium-99m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol2003 Dec; 92(2-3): 157-161.
11.
1996National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia.Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. N Z Med J1996 Jun 28; 109(1024): 224-231.
12.
Czuszynska Z., Romanowicz G.Myocardial perfusion in women with systemic lupus erythomatosus and no symptoms of coronary artery disease. Nucl Med Rev Cent East Eur2004; 7(2): 171-174.
13.
Hosenpud JD , Montanaro A., Hart MV, et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus . Am J Med1984Aug; 77(2): 286-292.
14.
McLaughlin MG, Danias PGTransient ischemic dilation: a powerful diagnostic and prognostic finding of stress myocardial perfusion imaging. J Nucl Cardiol2002 Nov-Dec; 9(6): 663-667.
15.
Nikpour M., Gladman DD, Ibanez D., Bruce IN, Burns RJ, Urowitz MBMyocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol2009 Feb; 36(2): 288-294.
Slart RH, Tio RA, Zijlstra F., Dierckx RADiagnostic pathway of integrated SPECT/CT for coronary artery disease . Eur J Nucl Med Mol Imaging2009 Nov; 36(11): 1829-1834.
19.
Underwood SR , Anagnostopoulos C., Cerqueira M., et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging2004 Feb; 31(2): 261-291.
20.
Kaminek M., Myslivecek M., Husak V., et al. The accuracy of myocardial perfusion SPECT imaging in the evaluation of coronary artery disease in women and men. Nucl Med Rev Cent East Eur2001; 4(2): 69-72.
21.
Fard-Esfahani A., Assadi M., Saghari M., et al. The role of myocardial perfusion imaging in the evaluation of patients undergoing percutaneous transluminal coronary angioplasty. Hellenic J Cardiol2009 Sep-Oct; 50(5): 396-401.
22.
Cooper JA, McCandless BKPreventing patient motion during tomographic myocardial perfusion imaging . J Nucl Med1995 Nov; 36(11): 2001-2005.
23.
Pitman AG, Kalff V., Van Every B., Risa B., Barnden LR, Kelly MJContributions of subdiaphragmatic activity, attenuation, and diaphragmatic motion to inferior wall artifact in attenuation-corrected Tc-99m myocardial perfusion SPECT. J Nucl Cardiol2005 Jul-Aug; 12(4): 401-409.
24.
Heller GV, Bateman TM, Johnson LL, et al. Clinical value of attenuation correction in stress-only Tc-99m sestamibi SPECT imaging. J Nucl Cardiol2004 May-Jun; 11(3): 273-281.
25.
Bengel FM, Schwaiger M.Nuclear medicine studies of the heart. Eur Radiol1998; 8(9): 1698-1706.
26.
Lagana B., Schillaci O., Tubani L., et al. Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Angiology1999 Feb; 50(2): 143-148.
27.
Alqaisi F., Albadarin F., Jaffery Z., et al. Prognostic predictors and outcomes in patients with abnormal myocardial perfusion imaging and angiographically insignificant coronary artery disease. J Nucl Cardiol2008 Nov-Dec; 15(6): 754-761.
28.
Delcour KS, Khaja A., Chockalingam A., Kuppuswamy S., Dresser T.Outcomes in patients with abnormal myocardial perfusion imaging and normal coronary angiogram. Angiology2009 Jun-Jul; 60(3): 318-321.
29.
Rasulova N. , Singh A., Demetriadou O., et al. Clinical significance of myocardial perfusion abnormalities in patients with varying degree of coronary artery stenosis. Nucl Med Commun2008 Feb; 29(2): 129-136.
30.
Gimelli A., Marzullo P., L’Abbate A., Rovai D.‘False-positive’ myocardial perfusion imaging: correlation with cardiovascular risk factors and effect on event-free survival. J Cardiovasc Med (Hagerstown) 2008 Jul; 9(7): 707-713.
31.
Adamu U., Knollmann D., Almutairi B., et al. Stress/rest myocardial perfusion scintigraphy in patients without significant coronary artery disease. J Nucl Cardiol2010 Jan-Feb; 17(1): 38-44.
32.
Soman P., Dave DM, Udelson JE, et al. Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery disease. J Nucl Cardiol2006 Nov; 13(6): 756-760.
33.
Iskandrian AEThe Achilles heel of SPECT imaging: the false-positive scans - or are they?J Nucl Cardiol Nov2006 Nov; 13(6): 747-748.
34.
Storto G., Sorrentino AR, Pellegrino T., Liuzzi R., Petretta M., Cuocolo A.Assessment of coronary flow reserve by sestamibi imaging in patients with typical chest pain and normal coronary arteries. Eur J Nucl Med Mol Imaging2007Aug; 34(8): 1156-1161.
35.
Ammann P., Naegeli B., Rickli H., et al. Characteristics of patients with abnormal stress technetium Tc 99m sestamibi SPECT studies without significant coronary artery diameter stenoses. Clin Cardiol2003 Nov; 26(11): 521-524.
36.
Nishioka T. , Amanullah AM, Luo H., et al. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. J Am Coll Cardiol1999 Jun; 33(7): 1870-1878.
37.
Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation2008 Mar 11; 117(10): 1283-1291.
38.
Doria A., Shoenfeld Y., Wu R., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis2003 Nov; 62(11): 1071-1077.
39.
Maksimowicz-McKinnon K., Magder LS, Petri M.Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol2006 Dec; 33(12): 2458-2463.
40.
Haque S., Gordon C., Isenberg D., et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol2010 Feb; 37(2): 322-329.
41.
Petri M., Perez-Gutthann S., Spence D., Hochberg MCRisk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med1992 Nov; 93(5): 513-519.
42.
Manzi S., Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol1997 Mar 1; 145(5): 408-415.
43.
Jonsson H., Nived O., Sturfelt G.Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine ( Baltimore) 1989 May; 68(3): 141-150.
Asherson RA , Khamashta MA, Baguley E., Oakley CM, Rowell NR, Hughes GRMyocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q J Med1989 Dec; 73(272): 1103-1115.
46.
de Bandt M. , Benali K., Guillevin L., et al. Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. J Rheumatol1999 Jan; 26(1): 91-96.
47.
Ghirardello A., Doria A., Ruffatti A., et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?Ann Rheum Dis1994 Feb; 53(2): 140-142.
